Scarica l'app Stockscreener
73.25
4.11%
2.89
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Nektar Therapeutics Borsa (NKTR) Ultime notizie
A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Momentum And Undervaluation Signals - simplywall.st
NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - GlobeNewswire Inc.
Nektar Therapeutics stock hits 52-week high at 76.3 USD By Investing.com - Investing.com South Africa
Decoding Nektar Therapeutics (NKTR): A Strategic SWOT Insight - GuruFocus
Nektar Therapeutics jumps on Q4 results - MSN
Nektar Therapeutics Bets Big on Respag Phase 3 - TipRanks
Nektar Therapeutics (NKTR) Q3 Losses Narrow To US$35.5 Million Testing Bearish Narratives - simplywall.st
Oppenheimer Maintains Outperform on Nektar Therapeutics (NKTR) March 2026 - Meyka
Oppenheimer raises Nektar Therapeutics price target to $140 By Investing.com - Investing.com Australia
ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel ... - bdtonline.com
ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Oppenheimer raises Nektar Therapeutics price target to $140 - Investing.com Nigeria
Nektar Therapeutics (NKTR) PT Raised to $140 at Oppenheimer - StreetInsider
Nektar Therapeutics stock hits 52-week high at 76.3 USD - Investing.com Nigeria
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire
Nektar Q4 Earnings & Revenues Trump Estimates, Pipeline in Focus - TradingView
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Nektar Therapeutics (NKTR) Surges After Beating Q4 Expectations - GuruFocus
Nektar Therapeutics Q4 2025 Earnings Call Summary - Yahoo Finance
William Blair Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $70.36 - 富途牛牛
Nektar Therapeutics (NASDAQ:NKTR) Q4 2025 Earnings Call Transcript - Insider Monkey
NKTR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Nektar Therapeutics Q4 2025 earnings preview - MSN
Nektar Therapeutics (NKTR) Reports Q4 and Full Year 2025 Financi - GuruFocus
NKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - Sahm
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Highlights: Promising Phase 2B Results and ... By GuruFocus - Investing.com Canada
Nektar Therapeutics Reports 2025 Financial Results and Advances Rezpegaldesleukin to Phase 3 for Atopic Dermatitis - Minichart
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Highlights: Pro - GuruFocus
Nektar Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Nektar Therapeutics Q4 2025 shows cash boost and R&D expansion - Investing.com Canada
Nektar (NKTR) Q4 2025 Earnings Call Transcript - AOL.com
Nektar Therapeutics (NKTR) Posts Fourth Quarter Loss, Exceeds Revenue Projections - Bitget
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Nektar (NKTR) Reports Decrease in Q4 Revenue, Prepares for Phase 3 Trials - GuruFocus
Nektar Therapeutics (NASDAQ: NKTR) posts wider 2025 loss but boosts cash via equity raises - Stock Titan
Nektar: Q4 Earnings Snapshot - marketscreener.com
Nektar Therapeutics (NKTR) Misses Q4 EPS by 178c - StreetInsider
Nektar Therapeutics Q4 Swings to Loss, Revenue Declines - marketscreener.com
Earnings Flash (NKTR) Nektar Therapeutics Posts Q4 Loss Per Share $1.78, vs. FactSet Est of $2.47 Loss - marketscreener.com
Earnings Flash (NKTR) Nektar Therapeutics Reports Q4 Revenue $21.8M, vs. FactSet Est of $10.2M - marketscreener.com
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - StreetInsider
Securities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - The AI Journal
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain OfficersNKTR - PR Newswire
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics ... - Bluefield Daily Telegraph
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein - GlobeNewswire
NKTR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Nektar Therapeutics Class Action Notice: Robbins LLP - GlobeNewswire
Securities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Carroll County Mirror-Democrat
Nektar Therapeutics Faces Class Action Lawsuit - Intellectia AI
NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
NEKTAR THERAPEUTICS (NKTR) INVESTOR ALERT Investors With - GlobeNewswire
User - The Chronicle-Journal
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure ... - Caledonian Record
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Nektar - GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):